ArticleBMC cancer2026
IL20RB as a potential biomarker for prognosis in clear cell renal cell carcinoma.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClear cell renal cell carcinoma (ccRCC) is the most common subtype of renal cell carcinomas and is known for having the worst prognosis. It features a complex array of histone deacetylases (HDACs), which play varied roles in tumor progression and patient outcomes. Exploring the role and significance of HDACs in ccRCC can provide effective prognosis and treatment methods for ccRCC.
methodsWe investigated the expression patterns of HDAC family genes in renal cancer and stratified the disease into distinct subtypes based on their expression profiles using consensus clustering. For each subtype, we conducted differential expression analysis, pathway enrichment analysis, and drug sensitivity evaluation. We then developed and validated a prognostic model utilizing genes associated with the HDAC-based subtypes across multiple independent cohorts. Finally, we collected clinical ccRCC samples and validated the expression of key genes, including IL20RB, using real-time quantitative PCR.
resultsWe identified three clusters linked to distinct HDAC expression patterns that demonstrate varied prognosis and drug sensitivities in ccRCC. Multi-omic analysis revealed distinct mutation and CNV profiles among these clusters, highlighting unique molecular characteristics. Additionally, an 8-gene model risk score, derived from HDAC expression patterns, has proven reliable as a prognostic marker in both training and validation cohorts for ccRCC. Survival analysis also showed that IL20RB is a dependable prognostic factor for ccRCC. Moreover, a pan-cancer analysis suggested that IL20RB is associated with poor prognosis and the activation of metastasis pathways in various types of cancer. Then, compared with tumor surrounding normal tissues, IL20RB expression was significantly up-regulated in in ccRCC tissues at all stages.
conclusionOur study delineates the role of HDACs in ccRCC, shedding light on their influence on tumor heterogeneity, immune modulation, drug response, and molecular profiles. Notably, IL20RB is identified not only as a promising therapeutic target but also as a prognostic indicator, thereby advancing the development of targeted therapies and precision medicine for this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.